NEW YORK, February 11, 2013 – Sanofi SA (ADR) (NYSE:SNY) soared 2.41% to $47.62. The stock is up after the rejection of Novo Nordisk’s drug as the two firms have been competing to dominate the lucrative insulin market.
Recently, the Company reported 2012 results. Total sales increased 0.5% to €34,947 million. Vaccines reported 5.7% sales growth to €3,897 million. EPS was €6.20 versus €6.65 in 2011 due to the negative impact of €1.3 billion at CER on the business net income related to the Plavix® and Avapro® losses of exclusivity in the U.S.
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) declined 3.42% to $0.512 on a traded volume of 45k shares. The Company provided an update on its research and development pipeline. The Company is primarily focused on rapidly advancing the development of FirdapseTM for the treatment of Lambert-Eaton Myasthenic Syndrome, which is the lead product candidate. Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare neurological diseases and disorders.
Rediff.com India Limited (ADR) (NASDAQ:REDF) soared 4.48% to $3.03 on a traded volume of 35k shares. Rediff.com India Limited publishes its unaudited consolidated balance sheet as of September 30, 2012 and its unaudited consolidated statement of income for the six months ended September 30, 2012. This is done in compliance with the NASDAQ Rule 5250(c) (2), which requires that each foreign private issuer with securities listed on the NASDAQ distribute interim financial information within six months following the end of such foreign private issuer's second fiscal quarter.
Csrnewsdaily.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCQBBB, OTCPINK Sheets, and NYSE has yielded considerable gains for our subscribers.
Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.
The assembled information disseminated by Csrnewsdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Csrnewsdaily.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Pacific Dynasty Consultants Inc.
2637 E Atlantic Blvd #22611 Pompano Beach, FL 33062